Adaptin Bio files S-1 to register resale of 382,400 shares from private placement
The registration also covers 38,240 shares tied to placement agent warrants held by Laidlaw & Company, as Adaptin advances its lead brain cancer program.
SEC filing
Latest
2 stories
Friday, August 28
Tuesday, August 25
Adaptin Bio opens Phase 1 trial of APTN-101 in glioblastoma with Duke University
The company announced on August 20, 2026 that enrollment has begun for a first-in-human study of its brain tumor-targeting bispecific T cell engager, run at Duke.
SEC filing